Guardant Health news

FDA approval of an expanded, more capable liquid biopsy test represents significant regulatory validation and competitive advancement. The test offers broader genomic coverage (100x wider), faster turnaround time (7 days), and integrated epigenomic insights. The stock price increased 8.81% on the news, reflecting positive market reception of this product expansion.

FDA approval of Guardant360 CDx companion diagnostic test validates the diagnostic tool and strengthens Guardant's multi-year collaboration with AstraZeneca, supporting future revenue opportunities.

Guardant Health is identified as a key player in the blood-based biomarkers market, particularly in liquid biopsy and oncology diagnostics.

Listed among key market participants specializing in liquid biopsy and biomarker testing, well-positioned in a high-growth market segment.

Included as a leading player positioned to benefit from growing adoption of liquid biopsy technologies in ovarian cancer diagnostics.

Markets competing Shield MCED test; represents competitive pressure on Grail but no specific developments discussed.

Identified as a key company in the growing AI cancer diagnostics market.

Key player in liquid biopsy and circulating tumor DNA (ctDNA) analysis, which are highlighted as rapidly advancing non-invasive diagnostic technologies driving market expansion.

Guardant360 CDx companion diagnostic approval enables non-invasive blood-based patient identification for VEPPANU treatment, expanding the utility of its liquid biopsy platform.

Included among industry leaders in oncology biomarkers, well-positioned for growth in liquid biopsy and cancer screening technologies.

Mentioned only as a top holding in Driehaus Capital's portfolio with no specific news or developments related to the company in this article. Inclusion is incidental to the investment discussion.